Is testing the key to unlocking PrEP scale-up? The use of antiretroviral drugs (ARVs) to prevent new HIV infections has been well-established for decades, particularly in the context of pre-exposure prophylaxis (PrEP). Yet, only an estimated 2.5 million people are currently using PrEP—far fewer than the 10 million needed to meet global HIV prevention goals by the end of 2025. A key barrier to PrEP scale-up is the challenge of HIV testing, which often requires frequent facility visits and relies on complex and costly testing technologies and algorithms. This session will present the latest evidence and best practices to ensure safe, accurate, and effective HIV testing, including self-testing, as part of PrEP delivery across various agents and service delivery models. It will also address emerging data on Long-acting Early Viral Inhibition (LEVI) with long-acting PrEP agents and propose a public health approach to testing that can support the implementation of these evolving PrEP tools.
CROI Conference
